HomeComparePFES vs JNJ

PFES vs JNJ: Dividend Comparison 2026

PFES yields 3.85% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFES wins by $5.7K in total portfolio value
10 years
PFES
PFES
● Live price
3.85%
Share price
$51.93
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.7K
Annual income
$493.23
Full PFES calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — PFES vs JNJ

📍 PFES pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPFESJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PFES + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PFES pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PFES
Annual income on $10K today (after 15% tax)
$327.36/yr
After 10yr DRIP, annual income (after tax)
$419.25/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $284.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PFES + JNJ for your $10,000?

PFES: 50%JNJ: 50%
100% JNJ50/50100% PFES
Portfolio after 10yr
$22.9K
Annual income
$660.51/yr
Blended yield
2.89%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

PFES
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PFES buys
0
JNJ buys
0
No recent congressional trades found for PFES or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPFESJNJ
Forward yield3.85%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$25.7K$20.0K
Annual income after 10y$493.23$827.78
Total dividends collected$4.4K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PFES vs JNJ ($10,000, DRIP)

YearPFES PortfolioPFES Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,085$385.13$10,676$355.77+$409.00PFES
2$12,260$399.00$11,407$389.39+$853.00PFES
3$13,531$412.42$12,198$426.53+$1.3KPFES
4$14,903$425.38$13,056$467.62+$1.8KPFES
5$16,384$437.88$13,987$513.12+$2.4KPFES
6$17,981$449.91$14,998$563.56+$3.0KPFES
7$19,701$461.45$16,098$619.52+$3.6KPFES
8$21,553$472.52$17,295$681.69+$4.3KPFES
9$23,545$483.11$18,599$750.82+$4.9KPFES
10$25,686$493.23$20,022$827.78+$5.7KPFES

PFES vs JNJ: Complete Analysis 2026

PFESStock

Under normal market circumstances, the adviser will maintain at least 80% exposure to financial instruments that provide two times inverse leveraged exposure to the daily performance of PFE. The fund is an actively-managed ETF that seeks to achieve on a daily basis, before fees and expenses, -200% performance of PFE for a single day, not for any other period, by entering into one or more swap agreements on PFE. The fund is non-diversified.

Full PFES Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this PFES vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PFES vs SCHDPFES vs JEPIPFES vs OPFES vs KOPFES vs MAINPFES vs ABBVPFES vs MRKPFES vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.